These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11697836)

  • 1. A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.
    Skovsgaard T; Davidson NG; Piccart MJ; Richel DJ; Bonneterre J; Cirkel DT; Barton CM;
    Ann Oncol; 2001 Sep; 12(9):1255-7. PubMed ID: 11697836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
    Rivera E; Sutton L; Colwell B; Graham M; Frye D; Somerville M; Conklin HS; McGuirt C; Levin J; Hortobagyi GN
    J Clin Oncol; 2002 Feb; 20(4):987-93. PubMed ID: 11844821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
    Jones SF; Greco FA; Hainsworth JD; Patton JW; Barton JH; Willcutt NT; Baker MN; McGuirt PV; Levin J; Burris HA
    Oncologist; 2002; 7(5):444-50. PubMed ID: 12401907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
    Smith IE; Johnston SR; O'Brien ME; Hickish TF; de Boer RH; Norton A; Cirkel DT; Barton CM
    J Clin Oncol; 2000 Jun; 18(12):2378-84. PubMed ID: 10856097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
    Schilsky RL; Bukowski R; Burris H; Hochster H; O'Rourke M; Wall JG; Mani S; Bonny T; Levin J; Hohneker J
    Ann Oncol; 2000 Apr; 11(4):415-20. PubMed ID: 10847459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    Llovet JM; Ruff P; Tassopoulos N; Castells L; Bruix J; El-Hariry I; Peachey M
    Eur J Cancer; 2001 Jul; 37(11):1352-8. PubMed ID: 11435064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
    Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
    Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
    Benson AB; Mitchell E; Abramson N; Klencke B; Ritch P; Burnhan JP; McGuirt C; Bonny T; Levin J; Hohneker J
    Ann Oncol; 2002 Apr; 13(4):576-81. PubMed ID: 12056708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
    Rothenberg ML; Benedetti JK; Macdonald JS; Seay TE; Neubauer MA; George CS; Tanaka MS; Giguere JK; Pruitt BT; Abbruzzese JL
    Ann Oncol; 2002 Oct; 13(10):1576-82. PubMed ID: 12377645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies.
    Yip D; Karapetis C; Strickland AH; Steer C; Holford C; Knight S; Harper P
    Ann Oncol; 2003 Jun; 14(6):864-6. PubMed ID: 12796023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
    Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
    J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
    Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
    Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
    Morgan-Meadows S; Thomas JP; Mulkerin D; Berlin JD; Bailey H; Binger K; Volkman J; Alberti D; Feierabend C; Marrocha R; Arzoomanian RZ; Wilding G
    Invest New Drugs; 2002 Nov; 20(4):377-82. PubMed ID: 12448654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
    Marsh JC; Catalano P; Huang J; Graham DL; Cornfeld MJ; O'Dwyer PJ; Benson AB
    Clin Colorectal Cancer; 2002 May; 2(1):43-50. PubMed ID: 12453335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.